Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onset of bronchodilation with Symbicort versus Seretide, Ventolin, and placebo in COPD
2004-001724-20Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide, salmeterol + fluticasone and salbutamol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Change in forced expiratory volume in one second. Started Aug 2004; status: completed.
02
Drugs
budesonidesalmeterol + fluticasonesalbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2004-001724-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001724-20.